This is a condition affecting the choroid, a layer of blood vessels in the eye. It involves abnormal blood vessel growth (neovascularization) that can leak fluid and blood. This leakage can cause vision problems. It's often linked to specific types of aneurysms in the choroidal blood vessels.
Every report comes from a Lived member, sent anonymously.
Have you tried Eylea (Aflibercept) for Polypoidal Choroidal Vasculopathy?
Polypoidal choroidal vasculopathy (PCV) is an eye disease in which abnormal blood vessels grow in the choroid, the layer of blood vessels beneath the retina. These vessels form a branching network that ends in small bulges, or polyps. The polyps can leak fluid and bleed under the macula, the central part of the retina that you rely on for reading, recognizing faces and seeing fine detail. People usually notice blurred or dim vision, a smudge or blind spot in the center of what they look at, or straight lines that look bent. Because bleeding can happen suddenly, PCV sometimes causes a fast and significant drop in vision in one eye. Many eye specialists consider PCV a subtype of wet age-related macular degeneration (wet AMD), but it behaves differently enough that telling them apart affects which treatment works best.
Researchers do not yet know exactly why PCV develops. One leading idea is that blood flow in the choroid becomes congested, its vessels widen and the thin layer of tiny vessels next to the retina is starved of oxygen, which prompts new, fragile vessels to grow. Many affected eyes have an unusually thick choroid, which links PCV to a group of related conditions that includes central serous chorioretinopathy, a disorder in which fluid collects under the retina. Other eyes look more like typical macular degeneration. PCV is most often diagnosed between about 50 and 65. It is far more common in people of Asian descent, where it accounts for roughly a quarter to more than half of cases first thought to be wet AMD, and it is also seen in Black and white people. Studies have linked it with male sex, smoking and high blood pressure, and some of the same gene variants that raise the risk of macular degeneration. These are associations rather than proven causes, and there is no known way to prevent PCV.
Diagnosis is made by an ophthalmologist, ideally a retina specialist, after a dilated eye exam. The doctor may see orange-red nodules beneath the retina, along with fluid, bleeding or yellow deposits. The key test is indocyanine green angiography (ICGA). A dye is injected into an arm vein and photographed as it flows through the eye with infrared light, which shows the deeper choroidal vessels and makes the polyps stand out as bright spots. Optical coherence tomography (OCT), a quick scan that produces cross-section images of the retina, shows fluid and characteristic sharp, peaked bumps where polyps lift the retina's pigment layer. Where ICGA is not available, OCT findings can often identify PCV on their own. The distinction matters because PCV can be mistaken for typical wet AMD or central serous chorioretinopathy. Many cases are first recognized when an eye being treated for wet AMD keeps leaking despite regular injections, or when bleeding seems out of proportion to the size of the lesion.
Treatment aims to stop leakage and bleeding, close the polyps and protect central vision. It does not reverse damage that scarring has already caused, which is one reason to start promptly. The mainstay is a series of injections into the eye of medicines that block vascular endothelial growth factor (VEGF), a signal that drives abnormal vessels to grow and leak. These are called anti-VEGF medicines. Commonly used options include aflibercept (Eylea), ranibizumab (Lucentis) and faricimab (Vabysmo), all approved in the US for wet AMD. The eye is numbed first, and the injection usually takes only moments. Injections are typically given monthly at first, then spaced out if the eye stays dry. In large trials, many people gained a meaningful amount of vision, roughly two lines on an eye chart, during the first one to two years. Faricimab's evidence specifically in PCV is newer and comes from smaller studies. Anti-VEGF injections alone often dry the retina without fully closing the polyps. Adding photodynamic therapy (PDT) can close more of them. In PDT, a light-sensitive drug called verteporfin (Visudyne) is given through an arm vein and then activated by a low-energy laser aimed at the lesion. In one large trial, adding PDT to injections led to better vision at two years and fewer injections; in another, injections alone did about as well, so doctors weigh the choice eye by eye. PDT is not available everywhere and is used off label for PCV. After verteporfin, skin and eyes must be kept out of direct sunlight and bright indoor light for five days. Polyps well away from the center of vision can sometimes be sealed with a conventional heat laser. Surgery is reserved for complications, such as a large bleed into the gel that fills the eye.
PCV is usually a long-term condition that needs ongoing care rather than a single course of treatment. The course varies a great deal. Some eyes, particularly those with a small isolated polyp and little bleeding, stay fairly stable, while eyes with clusters of polyps, large bleeds or scarring are more likely to lose vision. The other eye can also become involved, although this happens less often than with typical wet AMD, so both eyes are checked at visits. Recurrence is common. More than half of people whose PCV goes quiet see it come back within about 18 months, so regular retina visits with OCT scans continue even when vision feels steady. Frequent appointments and injections can be a real burden on time, travel and work, especially for those who need a driver after dilating drops. That burden leads some people to drop out of care, which puts vision at risk, so it helps to plan transport and scheduling early. If central vision is affected, low vision services can help with reading, lighting, magnifiers and phone or computer tools, and side vision usually remains useful for getting around.
See an eye doctor if you notice blurred or dim central vision, a smudge in the center of what you look at, or straight lines that look wavy, particularly if you are over 50 or of Asian descent. Checking each eye separately, for example with an Amsler grid, can make changes easier to spot. If you already have PCV or wet AMD, call your eye doctor right away about new distortion, a new dark or missing area, or a sudden drop in vision, since fresh bleeding is easiest to manage early. In the days after an eye injection, a red, painful or light-sensitive eye or worsening vision also needs a call to your eye doctor right away, because these can be signs of infection or retinal detachment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Polypoidal Choroidal Vasculopathy is like, what's helped you, or ask the community a question.